Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy
Copyright: © 2022 Ueno et al..
Loss-of-function mutations in genes encoding the Krebs cycle enzymes Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) induce accumulation of fumarate and succinate, respectively and predispose patients to hereditary cancer syndromes including the development of aggressive renal cell carcinoma (RCC). Fumarate and succinate competitively inhibit αKG-dependent dioxygenases, including Lysine-specific demethylase 4A/B (KDM4A/B), leading to suppression of the homologous recombination (HR) DNA repair pathway. In this study, we have developed new syngeneic Fh1- and Sdhb-deficient murine models of RCC, which demonstrate the expected accumulation of fumarate and succinate, alterations in the transcriptomic and methylation profile, and an increase in unresolved DNA double-strand breaks (DSBs). The efficacy of poly ADP-ribose polymerase inhibitors (PARPis) and temozolomide (TMZ), alone and in combination, was evaluated both in vitro and in vivo. Combination treatment with PARPi and TMZ results in marked in vitro cytotoxicity in Fh1- and Sdhb-deficient cells. In vivo, treatment with standard dosing of the PARP inhibitor BGB-290 and low-dose TMZ significantly inhibits tumor growth without a significant increase in toxicity. These findings provide the basis for a novel therapeutic strategy exploiting HR deficiency in FH and SDH-deficient RCC with combined PARP inhibition and low-dose alkylating chemotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Oncotarget - 13(2022) vom: 31., Seite 1054-1067 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ueno, Daiki [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.09.2022 Date Revised 07.06.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.18632/oncotarget.28273 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346447801 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346447801 | ||
| 003 | DE-627 | ||
| 005 | 20231226031501.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.28273 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346447801 | ||
| 035 | |a (NLM)36128328 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ueno, Daiki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.09.2022 | ||
| 500 | |a Date Revised 07.06.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright: © 2022 Ueno et al. | ||
| 520 | |a Loss-of-function mutations in genes encoding the Krebs cycle enzymes Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) induce accumulation of fumarate and succinate, respectively and predispose patients to hereditary cancer syndromes including the development of aggressive renal cell carcinoma (RCC). Fumarate and succinate competitively inhibit αKG-dependent dioxygenases, including Lysine-specific demethylase 4A/B (KDM4A/B), leading to suppression of the homologous recombination (HR) DNA repair pathway. In this study, we have developed new syngeneic Fh1- and Sdhb-deficient murine models of RCC, which demonstrate the expected accumulation of fumarate and succinate, alterations in the transcriptomic and methylation profile, and an increase in unresolved DNA double-strand breaks (DSBs). The efficacy of poly ADP-ribose polymerase inhibitors (PARPis) and temozolomide (TMZ), alone and in combination, was evaluated both in vitro and in vivo. Combination treatment with PARPi and TMZ results in marked in vitro cytotoxicity in Fh1- and Sdhb-deficient cells. In vivo, treatment with standard dosing of the PARP inhibitor BGB-290 and low-dose TMZ significantly inhibits tumor growth without a significant increase in toxicity. These findings provide the basis for a novel therapeutic strategy exploiting HR deficiency in FH and SDH-deficient RCC with combined PARP inhibition and low-dose alkylating chemotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a FH | |
| 650 | 4 | |a PARP inhibitor | |
| 650 | 4 | |a SDHB | |
| 650 | 4 | |a renal cell carcinoma | |
| 650 | 4 | |a temozolomide | |
| 650 | 7 | |a Fumarates |2 NLM | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 650 | 7 | |a Succinates |2 NLM | |
| 650 | 7 | |a Adenosine Diphosphate Ribose |2 NLM | |
| 650 | 7 | |a 20762-30-5 |2 NLM | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 650 | 7 | |a Dioxygenases |2 NLM | |
| 650 | 7 | |a EC 1.13.11.- |2 NLM | |
| 650 | 7 | |a Jumonji Domain-Containing Histone Demethylases |2 NLM | |
| 650 | 7 | |a EC 1.14.11.- |2 NLM | |
| 650 | 7 | |a Succinate Dehydrogenase |2 NLM | |
| 650 | 7 | |a EC 1.3.99.1 |2 NLM | |
| 650 | 7 | |a KDM4A protein, human |2 NLM | |
| 650 | 7 | |a EC 1.5.- |2 NLM | |
| 650 | 7 | |a Poly (ADP-Ribose) Polymerase-1 |2 NLM | |
| 650 | 7 | |a EC 2.4.2.30 |2 NLM | |
| 650 | 7 | |a Fumarate Hydratase |2 NLM | |
| 650 | 7 | |a EC 4.2.1.2 |2 NLM | |
| 650 | 7 | |a Lysine |2 NLM | |
| 650 | 7 | |a K3Z4F929H6 |2 NLM | |
| 650 | 7 | |a Temozolomide |2 NLM | |
| 650 | 7 | |a YF1K15M17Y |2 NLM | |
| 700 | 1 | |a Vasquez, Juan C |e verfasserin |4 aut | |
| 700 | 1 | |a Sule, Amrita |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Jiayu |e verfasserin |4 aut | |
| 700 | 1 | |a van Doorn, Jinny |e verfasserin |4 aut | |
| 700 | 1 | |a Sundaram, Ranjini |e verfasserin |4 aut | |
| 700 | 1 | |a Friedman, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Caliliw, Randy |e verfasserin |4 aut | |
| 700 | 1 | |a Ohtake, Shinji |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Xun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Huihui |e verfasserin |4 aut | |
| 700 | 1 | |a Boyd, Karla |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Rong Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Dodson, Jack |e verfasserin |4 aut | |
| 700 | 1 | |a Boutros, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Bindra, Ranjit S |e verfasserin |4 aut | |
| 700 | 1 | |a Shuch, Brian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 13(2022) vom: 31., Seite 1054-1067 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:31 |g pages:1054-1067 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.28273 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 31 |h 1054-1067 | ||